Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Tofacitinib

EULAR 2013: Drugs New and Old Could Treat Spondylarthropies

Thomas R. Collins  |  September 1, 2013

Nonsteroidal anti-inflammatory drugs (NSAIDs) might still have a role in treating axial spondylarthritis, but other drugs, therapies are being explored

Filed under:AnalgesicsAxial SpondyloarthritisBiologics/DMARDsConditionsDrug UpdatesMeeting Reports Tagged with:axial spondyloarthritis (SpA)drug therapyEULARNSAIDs

ACR 2013 State-of-the-Art Clinical Symposium: What’s Next in Therapy for Osteoarthritis, Rheumatoid Arthritis, and Lupus?

Kathy Holliman  |  August 1, 2013

Experts highlight treatment advances and challenges ahead in OA, RA, and systemic lupus erythematosus (SLE)

Filed under:ConditionsMeeting ReportsOsteoarthritis and Bone DisordersRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:AC&RLupusOsteoarthritisRheumatoid arthritisSLETreatment

ACR Winter Rheumatology Symposium: New Kinase Inhibitors Show Promise

Staff  |  May 1, 2013

Toxicity and appropriate targeting are challenges for small molecule researchers

Filed under:Drug UpdatesMeeting ReportsResearch Rheum Tagged with:AC&RACR Winter Rheumatology Symposiumkinase inhibitorResearch

Panel Addresses Drug Safety Issues in Rheumatology Products

Thomas R. Collins  |  February 15, 2013

Black box warnings, TNF inhibitors, and tofacitinib discussed

Filed under:Uncategorized Tagged with:FDAjanus kinase inhibitorTNF inhibitorsTofacitinib

ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines

Thomas R. Collins  |  February 1, 2013

People with rheumatic diseases can be considered to receive flu and pneumococcal vaccines even if they’re on immunosuppressive drugs

Filed under:ConditionsMeeting Reports Tagged with:DrugsImmune Systempatient carevaccine

ACR/ARHP Annual Meeting 2012: Late-Breaking Abstracts Bring Newer Research to the Forefront

Mary Beth Nierengarten  |  January 1, 2013

Studies addressing rheumatoid arthritis (RA) flares, a potential new drug for psoriatic arthritis, and a novel agent in the treatment of active RA are among the highlights

Filed under:ConditionsMeeting ReportsPsoriatic ArthritisRheumatoid Arthritis Tagged with:ACR/ARHP Annual MeetingPsoriatic ArthritisRA flaresRheumatoid arthritis

Rheumatology Drug Updates

Michele B. Kaufman, PharmD, BCGP  |  January 1, 2013

Information on new approvals and medication safety rheumatologists need to know

Filed under:Drug Updates Tagged with:adalimumabDrugsFDAguidelineSafety

Rheumatology Drug Updates: Apremilast, Golimumab, and More

Michele B. Kaufman, PharmD, BCGP  |  November 1, 2012

Information on new approvals and medication safety rheumatologists need to know

Filed under:AnalgesicsAxial SpondyloarthritisBiologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:Ankylosing SpondylitisBiologicsBiosimilarsdrugFDAinfliximabJAK inhibitorsjanus kinaseMethotrexatePipelinePolymyalgia RheumaticaprednisonePsoriatic ArthritisRheumatoid arthritisSafetyTofacitinib

Drug Updates

Michele B. Kaufman, PharmD, BCGP  |  July 9, 2012

Information on new approvals and medication safety.

Filed under:AnalgesicsAxial SpondyloarthritisBiologics/DMARDsConditionsDrug UpdatesRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:Ankylosing SpondylitisBiologicsbiophosphonatesdrugJAK inhibitorsjanus kinaseMethotrexateopioidPainRheumatoid arthritisrheumatologistrituximabSafetySystemic lupus erythematosustocilizumabTofacitinib

Rheumatoid Arthritis Drugs May Cut Cardiovascular Risk

Kathleen Louden  |  April 6, 2012

Other studies at the ACR/ARHP Annual Scientific Meeting in November examined arthritis treatment, scleroderma screening.

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone DisordersRheumatoid ArthritisSystemic Sclerosis Tagged with:ACR/ARHP Annual MeetingcardiovasculardrugJuvenile idiopathic arthritisMethotrexateOsteoarthritisPainpatient careRheumatoid arthritisrheumatologistSclerodermaTofacitinibTreatment

  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences